The Alkaloid #5: The Fuzz on the Seed Coat
THE ALKALOID
Science, culture and capital — one dose at a time.
Issue #5 — April 30, 2026
THE ALKALOID
Science, culture, and capital — one dose at a time.
Issue #5 — April 30, 2026
THE DOSE
The Fuzz on the Seed Coat
For nearly ninety years, one of the great unsolved mysteries in the history of psychedelic chemistry was hiding in plain sight. Albert Hofmann, the Swiss chemist who first synthesized LSD in 1938, spent decades convinced that morning glory plants harbored a hidden fungus producing chemicals nearly identical to the lysergic acid derivatives he had pulled from rye ergot. The plant's psychedelic properties had been known to indigenous Mesoamerican cultures for centuries. The chemicals were measurable. But the fungus itself, the actual organism producing them, eluded every scientist who looked for it.
The mystery has now been solved by a microbiology undergraduate from West Virginia University.
Corinne Hazel, an environmental microbiology major and Goldwater Scholar from Delaware, Ohio, was working in a lab studying how morning glory plants disperse protective chemicals through their roots. She wasn't looking for psychedelics. She wasn't looking for anything Hofmann had spent his life chasing. She was examining seed coats from a pile of plants when she noticed a small wisp of white fuzz that most people would have ignored entirely. The fuzz turned out to be the fungus.
Hazel and her advisor Daniel Panaccione, the Davis-Michael Professor of Plant and Soil Sciences at WVU, extracted DNA from the sample and sent it for genome sequencing. The results confirmed it was a previously unknown species. They named it Periglandula clandestina, a nod to its remarkable ability to evade discovery for so long. Their findings were published in the peer-reviewed journal Mycologia in April 2025.
What makes the discovery scientifically significant goes beyond closing a historical loop. Periglandula clandestina appears to produce ergot alkaloids efficiently, and ergot alkaloids are already the backbone of multiple existing medications. They are used to treat migraines, dementia, and Parkinson's disease in modified forms, and they are the chemical foundation from which LSD itself was created. A fungus that produces these compounds reliably and in cultivable quantities opens substantial new pathways for pharmaceutical development.
There is also something poetic about the discovery. Hofmann searched for this organism for decades after creating one of the most consequential molecules of the twentieth century. He died in 2008 at the age of 102 without finding it. Seventeen years later, an undergraduate noticed something fuzzy on a seed coat in a West Virginia laboratory, and the answer he had been looking for since the 1930s was sitting under a microscope.
Sometimes the thing being searched for has been waiting in the corner of a room the whole time, visible only to whoever finally bothers to look closely enough.
QUICK HITS
- Genome sequenced and banked. The genetic sequence of Periglandula clandestina has been deposited in a public gene bank under Hazel's name. Future researchers worldwide can now access the sequence to study, cultivate, and potentially modify the fungus for pharmaceutical applications.
- Funded by a student grant. The genome sequencing was funded by a WVU Davis College Student Enhancement Grant that Hazel had secured herself. A reminder that pivotal scientific discoveries don't always require massive institutional budgets.
- Mexican morning glory tradition acknowledged. Indigenous Mesoamerican cultures recognized Ipomoea tricolor's psychoactive properties centuries before Hofmann. The plant was used ceremonially under the name ololiuqui, and Hofmann himself credited those traditions when he first investigated the species in the 1950s.
- Ergot alkaloids beyond LSD. The compound class includes methysergide for migraines, bromocriptine for Parkinson's disease, and ergotamine for vascular conditions. The pharmaceutical infrastructure for these compounds is well established, which gives Periglandula clandestina an unusually direct path toward medical applications.
- More fungal diversity expected. Researchers note that two separate fungi producing ergot alkaloids have been identified on other morning glory species. The discovery of clandestina suggests the broader morning glory family likely harbors additional undiscovered fungal partners.
SCIENCE DESK
What ergot alkaloids actually are
Ergot alkaloids are a chemically distinctive family of compounds produced exclusively by certain fungi. The most famous member is lysergic acid, which Hofmann modified in 1938 to create LSD. But the family is much larger and more medically diverse than that single application suggests.
Naturally occurring ergot alkaloids have a complex history. The fungus Claviceps purpurea, which grows on rye and other grains, produces ergot alkaloids that have caused mass poisonings throughout human history. Outbreaks of ergotism, sometimes called Saint Anthony's Fire, killed thousands in medieval Europe through gangrene, convulsions, and hallucinations from contaminated grain. Some historians have suggested ergot poisoning may have played a role in the Salem witch trials.
That same chemistry, isolated and modified, has produced some of the most useful medications in modern neurology. Methysergide treats migraines. Bromocriptine and pergolide treat Parkinson's disease. Ergotamine treats severe headaches. These applications have been quietly running in pharmacies for decades while the public conversation about ergot alkaloids has been dominated by their psychedelic derivative.
The discovery of Periglandula clandestina matters in this context because it offers a new and potentially more controllable source of these compounds. Unlike Claviceps purpurea, which grows on grain crops and can contaminate food supplies with toxic concentrations, Periglandula clandestina lives in symbiosis with morning glory plants and may prove easier to cultivate under laboratory conditions. If the fungus can be grown reliably at scale, it provides researchers and pharmaceutical developers with a stable, characterized source of ergot alkaloid chemistry.
For psychedelic medicine specifically, this could become significant. The current pharmaceutical synthesis of LSD analogs requires complex multi-step chemistry starting from lysergic acid that has historically been challenging to source legally. A cultivable fungal source changes that supply chain entirely.
MARKET WATCH
The Periglandula clandestina discovery has not yet produced obvious market movement, but the implications for psychedelic biotech valuations are worth tracking. Companies developing LSD-based therapeutics, including Definium Therapeutics, depend on stable supply chains for lysergic acid derivatives. A cultivable fungal source represents a potential cost reduction and supply security advantage for any company that secures research access to the strain.
The broader pharmaceutical implications extend beyond psychedelics. The migraine and Parkinson's drug categories alone represent billions of dollars in annual revenue, and existing ergot alkaloid medications largely depend on synthetic production or extraction from Claviceps purpurea cultures. Pharmaceutical companies pursuing improved formulations or new chemical analogs in these spaces have a meaningful new tool.
Worth noting is that the research access question is not yet settled. Hazel and Panaccione's published findings make the genome sequence public, but biological samples and cultivation protocols typically remain controlled by the originating institution for a period before being shared. Companies seeking to use Periglandula clandestina commercially will need to navigate either licensing agreements with WVU or independent isolation efforts using the published genetic data.
The cannabis market remains in regulatory limbo. The November hemp THC deadline approaches with no legislative resolution. State-by-state divergence continues. Capital flows in the psychedelic biotech sector remain healthy following the executive order, with Compass Pathways' priority voucher and AtaiBeckley's clinical pipeline drawing the most institutional attention.
THE LAST WORD
There is a quiet lesson in this story worth sitting with. Albert Hofmann was one of the most brilliant chemists of the twentieth century. He synthesized LSD, isolated psilocybin, and spent decades searching for a specific fungus he was convinced existed in morning glory plants. He never found it. He died in 2008 having lived through the rise, fall, and tentative return of psychedelic medicine, with that one specific question still unanswered.
The answer turned out to be visible to anyone willing to look at a seed coat under sufficient magnification. It did not require advanced equipment, massive funding, or institutional power. It required someone in the right place, looking carefully at the right thing, willing to investigate a small piece of fuzz that might have been ignored.
Most scientific progress happens this way. Not in the dramatic moments of major discovery, but in undergraduates noticing things in laboratories, in long quiet hours of patient looking, in the willingness to take a seemingly trivial observation seriously enough to follow it. The history of psychedelic medicine is full of such moments. Maria Sabina sharing psilocybin mushrooms with Western researchers in 1955. Hofmann himself accidentally absorbing LSD through his fingertips in 1943. Now Corinne Hazel, in 2025, finding what one of the field's founders had searched for across his entire career.
Plant medicine has always been like this. The knowledge is patient. It waits for the right people to arrive.
— The Alkaloid
Sources
- Mycologia — A new species of Periglandula symbiotic with the morning glory Ipomoea tricolor: https://doi.org/10.1080/00275514.2025.2483634
- WVU Today — WVU student discovers long-awaited mystery fungus sought by LSD's inventor: https://wvutoday.wvu.edu/stories/2025/06/02/wvu-student-makes-long-awaited-discovery-of-mystery-fungus-sought-by-lsd-s-inventor
- ScienceDaily — Student discovers long-awaited mystery fungus sought by LSD's inventor: https://www.sciencedaily.com/releases/2025/06/250602154912.htm
- Live Science — College student discovers psychedelic fungus that eluded LSD inventor: https://www.livescience.com/health/medicine-drugs/college-student-discovers-psychedelic-fungus-that-eluded-lsd-inventor
- SciTechDaily — Long-Awaited Mystery Fungus Sought by LSD's Inventor Found After 80-Year Search: https://scitechdaily.com/long-awaited-mystery-fungus-sought-by-lsds-inventor-found-after-80-year-search/
- ZME Science — Student Finds the Psychedelic Fungus the Inventor of LSD Spent His Life Searching For: https://www.zmescience.com/science/chemistry/psychedelic-fungus-search-hofmann/
- KnowRidge — Long-awaited mystery fungus sought by LSD's inventor discovered: https://knowridge.com/2025/06/long-awaited-mystery-fungus-sought-by-lsds-inventor-discovered/
The Alkaloid publishes every Tuesday. Forward this to someone who needs the dose. Subscribe for full access: thealkaloid.ghost.io
